HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Cosmetics Bill Gains Co-Sponsors, Opponents; Unilever, Revlon Acquisitions; More

This article was originally published in The Rose Sheet

Executive Summary

Two more democratic senators sign on as co-sponsors of the Personal Care Products Safety Act; Cruelty Free calls the bill a “step in the right direction,” while the Handmade Cosmetic Alliance opposes the legislation, saying it would “jeopardize more than 300,000” small companies. More news in brief.

You may also be interested in...



Sen. Feinstein’s Cosmetics Safety Bill Launches With GOP Cosponsor

The Personal Care Products Safety Act would preempt duplicative state-level requirements for ingredient use and manufacturer responsibilities, addressing what has become one of the foremost banes of industry in recent years, while increasing FDA’s authority over the sector and giving it new responsibilities with regard to ingredient safety review. Additional compliance requirements for industry could prove challenging, but the positive PR likely to result from the legislation could help soften the blow.

In Brief: FDA, EPA Sharing Data; Industry Lead-In-Cosmetics Petition Goes Unanswered; More

FDA could use data collected under the Toxic Substances Control Act to inform its risk-assessment work, a March 16 update indicates, announcing a memorandum of understanding between FDA and the Environmental Protection Agency. More news in brief.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel